carboplatin + larotaxel

Carboplatin + larotaxel is a chemotherapy drug combination used primarily for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). Carboplatin is an organoplatinum alkylating agent that works by causing DNA crosslinking and damage, leading to apoptosis of rapidly dividing cancer cells. Larotaxel is a taxane-class chemotherapeutic agent that stabilizes microtubules and inhibits their disassembly, thereby disrupting mitosis and inducing cell death. The combination leverages different mechanisms to destroy cancer cells more effectively than single agents alone. This regimen has been studied in chemotherapy-naïve patients with advanced NSCLC, showing feasibility and modest activity but with notable hematological toxicities such as neutropenia[2][8].